248 related articles for article (PubMed ID: 34799729)
1. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
[TBL] [Abstract][Full Text] [Related]
2. PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
[TBL] [Abstract][Full Text] [Related]
3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
4. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
6. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
Xu L; Wang P; Zhang W; Li W; Liu T; Che X
Front Oncol; 2021; 11():757498. PubMed ID: 34660327
[TBL] [Abstract][Full Text] [Related]
7. SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.
Shi AD; Zhao LM; Sheng GL; Zhang GN; Tang YC; Li KS; Zhang ZL
J Cell Mol Med; 2023 Sep; 27(17):2547-2561. PubMed ID: 37488750
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
Zhang C; You X; Zhang Q; Wang D
Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
11. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
12. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
13. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Mas L; Perrier A; Coulet F; Bachet JB
Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
[TBL] [Abstract][Full Text] [Related]
15. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
16. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
Wei Y; Chen W; Li Z; Xie K; Liu F
FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
[TBL] [Abstract][Full Text] [Related]
17. Pemigatinib Is Active in Some
Cancer Discov; 2020 May; 10(5):639. PubMed ID: 32245820
[TBL] [Abstract][Full Text] [Related]
18. The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma.
Yang Y; Yuan J; Liu Z; Cao W; Liu P
Front Oncol; 2022; 12():972550. PubMed ID: 35965590
[TBL] [Abstract][Full Text] [Related]
19. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]